Don Alfonso
Palm Coast, FLNPI 1073508917
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 399 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,226 and has fallen 98.5% since, to $32 in 2024.
Across 399 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Novo Nordisk$759
- AbbVie$622
- Amgen$581
- Astellas Pharma US Inc$539
- Pfizer$470
- plus $2K from 23 others
Across 48 payments — averaging $2879.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Adamas Pharmaceuticals, Inc.$120K
- Novartis$18K
What the payments were for
- Food & beverage$6,05998%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 95 | $1,019 |
| Novo Nordisk | 53 | $759 |
| AbbVie(2 entities) | 43 | $622 |
| Amgen(2 entities) | 29 | $581 |
| Astellas Pharma US Inc | 29 | $539 |
| Pfizer | 28 | $470 |
| Boehringer Ingelheim | 15 | $362 |
| Lilly USA, LLC | 18 | $308 |
| Johnson & Johnson(2 entities) | 7 | $259 |
| AstraZeneca | 15 | $239 |
| Merck | 9 | $137 |
| Novartis | 9 | $132 |
| Daiichi Sankyo Inc. | 7 | $117 |
| Otsuka America Pharmaceutical, Inc. | 6 | $98 |
| Arbor Pharmaceuticals, Inc. | 7 | $91 |
| Abbott | 5 | $69 |
| Kowa Pharmaceuticals America, Inc. | 5 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Eisai Inc. | 2 | $34 |
| IBSA Pharma Inc. | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Circassia Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Axonics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.